Regentis BiomaterialsRGNT -11.82%14 3-Year ROIIC % is 939.06 as of Dec. 2025, which is 1602% above its 10-year median of 55.19. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Regentis Biomaterials ranks better than 97.75% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Regentis Biomaterials's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 939.06%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Regentis Biomaterials's 3-Year ROIIC % or its related term are showing as below:
RGNT's 3-Year ROIIC % is ranked better than 97.75% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 1.67
vs RGNT: 939.06
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Regentis Biomaterials 3-Year ROIIC % Related Terms
Regentis Biomaterials 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Regentis Biomaterials's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGNT vs HBIO, MLSS, RVP: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regentis Biomaterials 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Regentis Biomaterials's 3-Year ROIIC % falls into.
Regentis Biomaterials's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -8.619 (Dec. 2025) - -1.407 (Dec. 2022) )
/
( 1.215 (Dec. 2025) - 1.983 (Dec. 2022) )
=
-7.212
/
-0.768
=
939.06%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Regentis Biomaterials (RGNT) has a 3-Year ROIIC % of 939.06 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Regentis Biomaterials and its competitors. This is 1602% above median its historical median of 55.19. According to the industry distribution chart, Regentis Biomaterials ranks #18 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 2.3%.
Is Regentis Biomaterials' 3-Year ROIIC % too high?
Regentis Biomaterials' current 3-Year ROIIC % of 939.06 is 1602% above median its 10-year median of 55.19. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.67. Regentis Biomaterials' value of 939.06 is 56131.1% above this industry median. Based on the distribution chart, Regentis Biomaterials ranks #18 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' 3-Year ROIIC % compare to HBIO and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #18 out of 799 companies for 3-Year ROIIC %. This places Regentis Biomaterials in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.67. Regentis Biomaterials' value of 939.06 is 56131.1% above this benchmark. While the company's 10-year median is 55.19 vs. the industry median of 1.67, Regentis Biomaterials has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.67, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regentis Biomaterials's current 3-Year ROIIC % of 939.06 is 56131.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Regentis Biomaterials and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regentis Biomaterials's current 3-Year ROIIC % is 939.06, which is 1602% above median its own 10-year median of 55.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current 3-Year ROIIC % of 939.06. The current 3-Year ROIIC % is 939.06, which is 1602% above median its 10-year median of 55.19 and 56131.1% above the Medical Devices & Instruments industry median of 1.67. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current 3-Year ROIIC % is 939.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score
Get the complete analysis for RGNT
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGNT has been successfully added to your 
